Assessment of incidence of inhibitors in patients with haemophilia

Haemophilia

Volumn 15, Issue 3, 2009, Pages 707-711

  van der Bom, Johanna G ^a   Ter Avest, P ^b   Van Den Berg, H M ^b   Psaty, B M ^c,d   Weiss, N S ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Group Health Centre for Health Studies   (United States)

Author keywords

Inhibitory; Risk; Selection

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; GENETIC RISK; HEMOPHILIA A; HUMAN; INCIDENCE; METHODOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VALIDITY;

AGE FACTORS; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; RISK ASSESSMENT; RISK FACTORS;

EID: 65549139189     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02002.x     Document Type: Article

References (35)

1. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94(Suppl 1): 49-52.
2. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002; 8(Suppl 2): 23-9.
3. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
4. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
5. Gouw SC, van den Berg HM, Le CS, van der Bom JG. Treatment characteristics and the risk of inhibitor development: A multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007; 5: 1383-90.
6. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
7. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
8. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost 1993; 69: 115-8.
9. US Food and Drug Administration (FDA). Office for Biologics Evaluation and Research and Office of Blood Research and Review and the International Association for Biologicals. The Factor VIII Inhibitor Workshop. 1-11-0111. Bethesda: FDA (Generic), 2003.
10. Committee for Medicinal Products for Human Use (CHMP). Concept paper on the Revision of Notes for Guidance on the Clinical Investigations of Human Plasma Derived and Recombinant Factor VIII and IX Products and the Corresponding Core SPCs. London: European Medicines Agency, 2008 (Generic).
11. Lee ML, Roth DA. A Bayesian approach to the assessment of inhibitor risk in studies of factor VIII concentrates. Haemophilia 2005; 11: 5-12.
12. Lusher JM. Hemophilia: Continued challenges but reason for optimism on many fronts. Transfusion 1993; 33: 791-3.
13. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
14. Gouw SC, van der Bom JG, Marijke van den BH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
15. White GC, DiMichele D, Mertens K et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1999; 81: 462.
16. Briet E, Rosendaal FR, Kreuz W et al. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994; 72: 162-4.
17. Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-1999. J Thromb Haemost 2004; 2: 1047-54.
18. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
19. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
20. ter Avest PC, Fischer K, Mancuso ME et al. Risk stratification for inhibitor development at first treatment for severe haemophilia A: A tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81. (Internet Communication).
22. Peerlinck K, Hermans C. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia 2006; 12: 579-90.
23. Rasi V, Ikkala E. Haemophiliacs with factor VIII inhibitors in Finland: prevalence, incidence and outcome. Br J Haematol 1990; 76: 369-71.
24. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. J Thromb Haemost 2006; 4: 2576-81.
25. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
26. Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/ Bioclate): A prospective pharmacovigilance study. Haemophilia 2004; 10: 491-8.
27. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997; 77: 660-7.
28. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med 1990; 323: 1800-5.
29. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: Conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia 1999; 5: 9-16.
30. Abshire TC, Brackmann HH, Scharrer I et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - International Kogenate-FS Study Group. Thromb Haemost 2000; 83: 811-6.
31. Yoshioka A, Shima M, Fukutake K, Takamatsu J, Shirahata A. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: A long-term, multicentre clinical study in Japan. Haemophilia 2001; 7: 242-9.
32. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-9.
33. Lusher JM, Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: An update. Haemophilia 2005; 11: 292-3.
34. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003; 9: 38-49.
35. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/ albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.